ImmuPharma PLC
LSE:IMM

Watchlist Manager
ImmuPharma PLC Logo
ImmuPharma PLC
LSE:IMM
Watchlist
Price: 6.86 GBX -4.72% Market Closed
Market Cap: 34.5m GBX

EV/EBIT
Enterprise Value to EBIT

-12.4
Current
-2.7
Median
16.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-12.4
=
Enterprise Value
33.9m GBX
/
EBIT
-2.7m GBP
All Countries
Close
EBIT Growth EV/EBIT to Growth
UK
ImmuPharma PLC
LSE:IMM
Average EV/EBIT: 1 883.5
Negative Multiple: -12.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.9
23%
6.9
CH
Novartis AG
SIX:NOVN
15.3
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A